An Open-label Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Phase of Trial: Phase I
Latest Information Update: 14 May 2015
At a glance
- Drugs Fedratinib (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Mar 2013 Actual initiation date changed from 1 Dec 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov record.
- 23 Jan 2013 New trial record